A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation

Clinical trial NCT06599502 · TERMINATED

Trial details

NCT number: NCT06599502
Sponsor: AstraZeneca
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Advanced Solid Tumours Non-Small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Colorectal Cancer (CRC)

Start date: 2024-10-18
Primary completion: 2025-10-20
Enrollment: 17

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.